NASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis → Who are Nvidia’s Silent Partners? (From Weiss Ratings) (Ad) Free PODD Stock Alerts $171.51 -9.57 (-5.28%) (As of 03:40 PM ET) Add Compare Share Share Today's Range$170.77▼$180.7250-Day Range$161.02▼$187.2752-Week Range$125.82▼$298.95Volume502,265 shsAverage Volume900,553 shsMarket Capitalization$12.01 billionP/E Ratio51.97Dividend YieldN/APrice Target$239.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Insulet alerts: Email Address Insulet MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.82 Rating ScoreUpside/Downside36.9% Upside$239.44 Price TargetShort InterestHealthy4.20% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment0.93Based on 6 Articles This WeekInsider TradingSelling Shares$1.89 M Sold Last QuarterProj. Earnings Growth20.90%From $3.11 to $3.76 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.96 out of 5 starsMedical Sector24th out of 921 stocksSurgical & Medical Instruments Industry6th out of 98 stocks 4.4 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 14 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageInsulet has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insulet's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.20% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 2.80%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 3.3 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Insulet this week, compared to 9 articles on an average week.Search Interest12 people have searched for PODD on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows8 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,891,338.00 in company stock.Percentage Held by InsidersOnly 0.47% of the stock of Insulet is held by insiders.Read more about Insulet's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 20.90% in the coming year, from $3.11 to $3.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 53.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.37.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 53.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.99.Price to Earnings Growth RatioInsulet has a PEG Ratio of 3.29. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 15.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insulet's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Insulet Stock (NASDAQ:PODD)Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More PODD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PODD Stock News HeadlinesMay 22 at 1:06 PM | finance.yahoo.comInsulet Corporation (PODD)May 19, 2024 | investorplace.comFollow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit GainsMay 15, 2024 | americanbankingnews.comBarclays Cuts Insulet (NASDAQ:PODD) Price Target to $200.00May 14, 2024 | au.investing.comBlue Orca goes short Insulet on undisclosed preliminary injunction defeatMay 14, 2024 | finance.yahoo.comWall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday?May 14, 2024 | finance.yahoo.comWill Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems MarketMay 14, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)May 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Insulet (PODD)May 14, 2024 | americanbankingnews.comRaymond James Lowers Insulet (NASDAQ:PODD) Price Target to $213.00May 14, 2024 | americanbankingnews.comInsulet (NASDAQ:PODD) Price Target Increased to $260.00 by Analysts at Jefferies Financial GroupMay 13, 2024 | benzinga.comWhat the Options Market Tells Us About InsuletMay 13, 2024 | markets.businessinsider.comInsulet (PODD) Gets a Hold from Stifel NicolausMay 13, 2024 | americanbankingnews.comBrokers Offer Predictions for Insulet Co.'s Q2 2024 Earnings (NASDAQ:PODD)May 13, 2024 | americanbankingnews.comReviewing Insulet (NASDAQ:PODD) & Nemaura Medical (NASDAQ:NMRD)May 13, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Insulet (PODD) and Progyny (PGNY)May 12, 2024 | finance.yahoo.comResults: Insulet Corporation Beat Earnings Expectations And Analysts Now Have New ForecastsMay 12, 2024 | msn.comStreet calls of the week: Micron upgraded, downgrade for ZoomInfoMay 10, 2024 | markets.businessinsider.comInsulet Corporation: Strong Q1 Performance and Positive Growth Outlook Affirm Buy RatingMay 10, 2024 | markets.businessinsider.comBank of America Securities Reaffirms Their Buy Rating on Insulet (PODD)May 10, 2024 | finance.yahoo.comInsulet Corp (PODD) Reports Strong Q1 2024 Results and Raises Full-Year GuidanceMay 10, 2024 | finance.yahoo.comInsulet Corporation (NASDAQ:PODD) Q1 2024 Earnings Call TranscriptMay 9, 2024 | investorplace.comPODD Stock Earnings: Insulet Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | seekingalpha.comInsulet Corporation 2024 Q1 - Results - Earnings Call PresentationMay 9, 2024 | yahoo.comInsulet misses first-quarter profit estimates as marketing costs weighMay 9, 2024 | msn.comInsulet Non-GAAP EPS of $0.23 misses by $0.16, revenue of $441.7M beats by $18.21MSee More Headlines Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/23/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees3,000Year Founded2000Price Target and Rating Average Stock Price Target$239.44 High Stock Price Target$330.00 Low Stock Price Target$184.00 Potential Upside/Downside+36.2%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$3.30 Trailing P/E Ratio53.29 Forward P/E Ratio56.54 P/E Growth3.29Net Income$206.30 million Net Margins13.14% Pretax Margin13.75% Return on Equity34.06% Return on Assets9.08% Debt Debt-to-Equity Ratio1.72 Current Ratio3.74 Quick Ratio2.75 Sales & Book Value Annual Sales$1.70 billion Price / Sales7.26 Cash Flow$3.65 per share Price / Cash Flow48.17 Book Value$11.29 per share Price / Book15.58Miscellaneous Outstanding Shares70,040,000Free Float69,711,000Market Cap$12.32 billion OptionableOptionable Beta1.00 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. James R. Hollingshead Ph.D. (Age 61)President, CEO & Director Comp: $2.88MMs. Laetitia Cousin (Age 48)Senior VP of Regulatory Affairs, Quality Assurance & Compliance Angela Geryak WiczekSenior Director of Corporate CommunicationsMr. Philip HildaleSenior Vice President of Sales & Customer CareKey CompetitorsTeleflexNYSE:TFXGlobus MedicalNYSE:GMEDAbiomedNASDAQ:ABMDBaxter InternationalNYSE:BAXiRhythm TechnologiesNASDAQ:IRTCView All CompetitorsInsiders & InstitutionsBeck Bode LLCBought 20,373 shares on 5/22/2024Ownership: 0.100%Swedbank ABBought 40,277 shares on 5/21/2024Ownership: 0.058%Virtu Financial LLCSold 202 shares on 5/20/2024Ownership: 0.008%Motley Fool Asset Management LLCBought 93 shares on 5/17/2024Ownership: 0.002%iA Global Asset Management Inc.Bought 614 shares on 5/17/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions PODD Stock Analysis - Frequently Asked Questions Should I buy or sell Insulet stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PODD shares. View PODD analyst ratings or view top-rated stocks. What is Insulet's stock price target for 2024? 17 Wall Street analysts have issued 1-year price objectives for Insulet's shares. Their PODD share price targets range from $184.00 to $330.00. On average, they anticipate the company's stock price to reach $239.44 in the next twelve months. This suggests a possible upside of 36.9% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts. How have PODD shares performed in 2024? Insulet's stock was trading at $216.98 at the beginning of 2024. Since then, PODD stock has decreased by 19.4% and is now trading at $174.96. View the best growth stocks for 2024 here. When is Insulet's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our PODD earnings forecast. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) released its quarterly earnings results on Thursday, May, 9th. The medical instruments supplier reported $0.73 EPS for the quarter, topping the consensus estimate of $0.39 by $0.34. The medical instruments supplier earned $441.70 million during the quarter, compared to the consensus estimate of $424.05 million. Insulet had a net margin of 13.14% and a trailing twelve-month return on equity of 34.06%. Insulet's revenue was up 23.3% on a year-over-year basis. During the same period last year, the company posted $0.23 EPS. What ETFs hold Insulet's stock? ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Fidelity Digital Health ETF (FDHT), Goldman Sachs Future Health Care Equity ETF (GDOC), Fidelity Disruptive Medicine ETF (FMED), Tema Cardiovascular and Metabolics ETF (HRTS), Invesco Focused Discovery Growth ETF (IVDG), First Trust Indxx Medical Devices ETF (MDEV) and Congress SMid Growth ETF (CSMD). What guidance has Insulet issued on next quarter's earnings? Insulet updated its second quarter 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $456.0 million-$467.9 million, compared to the consensus revenue estimate of $457.8 million. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD). Who are Insulet's major shareholders? Insulet's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.71%), Capital Research Global Investors (10.80%), Baillie Gifford & Co. (2.06%), Clearbridge Investments LLC (1.81%), William Blair Investment Management LLC (1.36%) and Westfield Capital Management Co. LP (0.67%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PODD) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersThis could mean the end of the U.S dollar…Colonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaElon to Transform U.S. Economy? Porter & CompanyThe Presidential candidate you should REALLY be worried aboutStansberry ResearchThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarU.S. Drone Company Receives DoD CertificationThe Tomorrow InvestorExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
